.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Baxter
AstraZeneca
Medtronic
Dow
Boehringer Ingelheim
Fish and Richardson
Federal Trade Commission
Harvard Business School
Novartis

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090877

« Back to Dashboard
NDA 090877 describes RISEDRONATE SODIUM, which is a drug marketed by Teva Pharms Usa, Macleods Pharms Ltd, Aurobindo Pharma Ltd, Apotex Inc, Mylan Pharms Inc, and Sun Pharma Global, and is included in nine NDAs. It is available from seven suppliers. Additional details are available on the RISEDRONATE SODIUM profile page.

The generic ingredient in RISEDRONATE SODIUM is risedronate sodium. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the risedronate sodium profile page.

Summary for 090877

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Metabolic Bone Disease Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 090877

Ingredient-typeDiphosphonates

Medical Subject Heading (MeSH) Categories for 090877

Suppliers and Packaging for NDA: 090877

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RISEDRONATE SODIUM
risedronate sodium
TABLET;ORAL 090877 ANDA Apotex Corp. 60505-3096 60505-3096-2 1 BLISTER PACK in 1 CARTON (60505-3096-2) > 2 TABLET, FILM COATED in 1 BLISTER PACK
RISEDRONATE SODIUM
risedronate sodium
TABLET;ORAL 090877 ANDA Apotex Corp. 60505-3097 60505-3097-2 1 BLISTER PACK in 1 CARTON (60505-3097-2) > 1 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength35MG
Approval Date:Nov 30, 2015TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength75MG
Approval Date:Jun 10, 2014TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG
Approval Date:Jun 10, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Daiichi Sankyo
UBS
QuintilesIMS
McKesson
Covington
McKinsey
Baxter
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot